271
Participants
Start Date
May 10, 2011
Primary Completion Date
January 30, 2012
Study Completion Date
January 30, 2012
lisdexamfetamine dimesylate (SPD489)
SPD489-30mg capsules taken once daily for up to 11 weeks
lisdexamfetamine dimesylate (SPD489)
SPD489 50mg capsules taken once-daily for up to 11 weeks
lisdexamfetamine dimesylate (SPD489)
SPD489 70mg capsule taken once-daily for up to 11 weeks
Placebo
Placebo capsule taken once daily for up to 11 weeks
Richmond Behavioral Associates, Staten Island
Marc Hertzman, MD, PC, Rockville
Charlottesville Medical Research, Charlottesville
Wake Research Associates, Raleigh
Weight Management Center, Medical University of South Carolina, Charleston
Carman Research, Smyrna
Atlanta Institute of Medicine and Research, Atlanta
Clinical Neuroscience Solutions, Inc., Jacksonville
Florida Clinical Research, Bradenton
Clinical Neuroscience Solutions, Inc., Orlando
Gulfcoast Clinical Research, Fort Myers
Clinical Neuroscience Solutions, Inc., Memphis
Lindner City of Hope, Mason
Community Research, Cincinnati
Unniversity of Minnesota, Minneapolis
Neuropsychiatric Research Institute, Fargo
Capstone Clinical Research, Libertyville
Weight Disorders Washington University School of Medicine, Dept of Psychiatry, St Louis
Clinical Trials Technology, Inc., Prairie Village
Vince and Assoc. Research, Overland Park
Louisiana Research Associates, Inc., New Orleans
Clinical Study Centers, LLC, Little Rock
Drug Development, Inc., Houston
FutureSearch Clinical Trials, Austin
Robert Lynn Horne, MD, Las Vegas
Southwestern Research, Inc., Beverly Hills
Scripps Clinical Research Services, La Jolla
PCSD - Feighner Research, San Diego
Pharmacology Research Institute, Newport Beach
McLean Hospital, Belmont
Boston Clinical Trials, Boston
Lead Sponsor
Shire
INDUSTRY